pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,617 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1875Endpoints1455Fierce Biotech771BioSpace762BioPharma Dive550raps249onclive165fda recalls
therapy area
allOncology12965Rare Disease3357Immunology3052Cardiology2859Hematology2304Pulmonology2255Vaccines
  • Pfizer CEO warns China will be major biotech competitor by 2030 and urges AI-driven cost cuts
    At the Jefferies Global Healthcare Conference in London, Pfizer chief Albert Bourla said China is rapidly building its biotech sector and could become the company's biggest rival by 2030, surpassin…
    BioSpace · 1d agoNeutral↗ source
  • FDA rejects Summit Therapeutics' ivonescimab, citing trial design and safety concerns
    Summit Therapeutics received a Complete Response Letter from the FDA rejecting its application for ivonescimab, a PD-1xVEGF combination intended for EGFR-mutated non-small cell lung cancer. The ag…
    BioSpace · 1d agoRegulatoryNegative↗ source
← prev
page 2 of 105
next →
120
fda medwatch115
globenewswire health73
fda press62
1861
Psychiatry & CNS1234
Ophthalmology1138
Endocrinology & Metabolism809
Pain792
Nephrology787
  • Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater China
    Pfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…
    Endpoints · 1d agoDealPositive↗ source
  • Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchase
    Merck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…
    Endpoints · 1d agoDealNegative↗ source
  • Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challenges
    Acquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
    BioSpace · 1d agoDealNeutral↗ source
  • Biogen's low-dose tau drug shows greater slowing of Alzheimer’s progression after two years
    Biogen reported new data on its experimental tau-reducing therapy diranersen, showing that the lowest dose continued to slow Alzheimer’s disease progression after nearly two years of treatment. Th…
    Endpoints · 1d agoPositive readoutPositive↗ source
  • White House withdraws Trump nominee Heidi Overton from FDA commissioner consideration amid Senate doubts
    The White House announced it has pulled Heidi Overton, the Trump administration’s nominee to serve as commissioner of the Food and Drug Administration. Overton’s nomination had been moving through…
    Endpoints · 1d agoRegulatoryNegative↗ source
  • Novo accelerates consumer focus with Wegovy pill launch and upcoming CagriSema, as marketing chief Ed Cinca returns
    Novo is intensifying its consumer‑focused strategy, highlighted by the Wegovy oral pill and the forthcoming CagriSema product. The effort coincides with the return of senior vice president of mark…
    Endpoints · 22h agoPositive↗ source
  • Eli Lilly's Alzheimer's drug mevidalen fails Phase 2 trial
    Eli Lilly conducted a Phase 2 trial of mevidalen, a dopamine-modulating compound, in patients with mild to moderate Alzheimer's disease. The study did not meet its primary efficacy endpoints, indi…
    Endpoints · 1d agoNegative readoutNegative↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination amid Senate opposition
    The White House pulled the nomination of Heidi Overton for FDA commissioner just hours before the Senate Health, Education, Labor, and Pensions (HELP) committee was set to vote. Overton, who serve…
    BioSpace · 1d agoRegulatoryNegative↗ source
  • Heidi Overton’s FDA nomination stalls as Senate HELP Committee vote fails
    Heidi Overton, the Trump administration’s pick for FDA commissioner, faced a decisive vote before the Senate HELP Committee less than a day after her testimony. The committee’s deliberations were…
    Endpoints · 18h agoRegulatoryNegative↗ source
  • Hims & Hers adds peptide and longevity treatments to its telehealth lineup
    Hims & Hers announced on Wednesday that it is now offering a range of peptide-based products and other treatments marketed for longevity and wellness. The new portfolio expands the company's teleh…
    Endpoints · 22h agoPositive↗ source
  • Jefferies Global Healthcare Conference Highlights AI, PI3Kα and Protein Degrader Strategies
    Long queues formed outside the Waldorf Hilton in London as attendees arrived for the 17th Jefferies Global Healthcare Conference. The event gathered investors, executives and scientists eager to he…
    Endpoints · 1d agoNeutral↗ source
  • 8 companies hiring in North Carolina now
    Looking for a biopharma role in North Carolina? Jobs on BioSpace increased significantly year over year in October. Check out the open positions posted now for life sciences professionals like you.
    BioSpace · 1d agoRegulatoryNeutral↗ source
  • BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026
    BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…
    BioSpace · 1d agoNeutral↗ source
  • Why comparing every new employer to your last one can hurt your influence
    Executive coach Angela Justice advises professionals not to treat their former workplace as the standard for every new job. She says the habit can cloud judgment and reduce a person's influence. W…
    BioSpace · 1d agoNeutral↗ source
  • CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
    Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…
    BioSpace · 1d ago↗ source
  • Isomorphic Labs lands record $5 billion Series C, marking biggest private biotech raise ever
    Isomorphic Labs, a Google-backed biotech company, announced a $5 billion Series C financing round. The round, completed just six months after a $2.1 billion raise, is the largest private capital r…
    Endpoints · 2d agoDealPositive↗ source
  • Isomorphic Labs raises record $5 billion in Series C, doubling its May funding
    Isomorphic Labs, an AI-driven drug design company, announced a $5 billion Series C financing, the largest private biotech raise ever and more than double its $2.1 billion Series B from May. The ro…
    BioSpace · 2d agoDealPositive↗ source
  • Vertex awaits FDA decision on povetacicept for IgA nephropathy, analysts expect approval
    Vertex Pharmaceuticals is awaiting an FDA ruling this month on its investigational drug povetacicept, being evaluated for the treatment of IgA nephropathy. Analysts, including Myles Minter of Will…
    BioSpace · 2d agoRegulatoryPositive↗ source
  • Sellas cancer vaccine cuts death risk by 41% in late-stage AML trial
    Sellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
    BioSpace · 2d agoPositive readoutPositive↗ source
  • Roche secures FDA approval for giredestrant, its first SERD for advanced breast cancer
    Roche announced that its experimental breast cancer drug giredestrant received FDA approval for treatment of patients with late‑stage disease. The approval places Roche into the selective estrogen…
    Endpoints · 2d agoApprovalPositive↗ source
  • GSK receives accelerated FDA approval for oral lung cancer drug neladalkib
    GSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
    Endpoints · 1d agoApprovalPositive↗ source
  • AriBio's AR1001 shows 31% slower cognitive decline in monotherapy Phase 3 trial
    AriBio presented data at the 2026 Clinical Trials on Alzheimer's Disease conference indicating its candidate AR1001 slowed cognitive decline compared with placebo in patients not taking other Alzhe…
    BioSpace · 2d agoPositive readoutPositive↗ source
  • Beren Therapeutics secures FDA approval for Lembaz to treat infantile-onset Niemann-Pick disease type C
    Beren Therapeutics announced that the U.S. Food and Drug Administration has approved its drug Lembaz for the treatment of infantile‑onset Niemann‑Pick disease type C, a rare and severe pediatric co…
    Endpoints · 1d agoApprovalPositive↗ source